BIOPHARMA
By
Can Bristol Myers Squibb’s $330 Million AI Investment in 2025 — Powered by Strategic Partnerships — Accelerate Discovery, R&D and Commercial Impact in 2026?
Global – December 31, 2025 — Bristol Myers Squibb (BMS) significantly expanded its commitment to artificial intelligence (AI)…
Can GSK’s $340 Million AI Investment in 2025 — Backed by Strategic Collaborations — Accelerate Discovery, R&D and Commercial Growth in 2026?
Global – December 31, 2025 — GlaxoSmithKline plc (GSK) significantly expanded its use of artificial intelligence (AI) throughout…
Can AstraZeneca’s $390 Million AI Investment in 2025 — Fueled by Strategic Partnerships — Accelerate Discovery, R&D, and Commercial Success in 2026?
Global – December 31, 2025 — AstraZeneca plc significantly expanded its commitment to artificial intelligence (AI) throughout 2025,…
Can Merck’s $300 Million AI Investment in 2025 — Fueled by Strategic Partnerships — Accelerate Innovation, R&D and Commercial Success in 2026?
Global – December 31, 2025 — Merck & Co., Inc. significantly expanded its commitment to artificial intelligence (AI)…
Merck Reinforces Oncology Leadership and Therapeutic Area Depth with Robust 2025 Performance
Rahway, NJ – February 2026 – Merck & Co., Inc. reported strong full-year 2025 financial and operational performance,…
AbbVie Accelerates Portfolio-Led Growth in 2025 and Strengthens Its Long-Term Therapeutic Leadership
North Chicago, IL – February 2026 – AbbVie Inc. reported a strong full-year financial performance in 2025, underscoring…
